Direkt zum Inhalt

Vallaster, Bernadette ; Forster, Lisa ; Bresinsky, Merlin Niklas ; Wirth, Lukas ; Fuller, Jessica L. ; Shibatani, K. ; Lapcinski, Ian P. ; Liu, Peng ; Mudaliar, Deepti ; Hubmann, Alexander ; Daschner, Jonas ; Pongratz, Herwig ; Ködel, Marlisa ; Yang, M. ; Ashe, Karen H. ; Walters, Michael A. ; Pockes, Steffen

Refinement of Peptidomimetics toward MUR-2425: A Brain-Penetrant and Selective Caspase-2 Inhibitor with Enhanced Pharmacokinetics

Artikel

Vallaster, Bernadette, Forster, Lisa , Bresinsky, Merlin Niklas , Wirth, Lukas, Fuller, Jessica L. , Shibatani, K., Lapcinski, Ian P., Liu, Peng, Mudaliar, Deepti, Hubmann, Alexander, Daschner, Jonas, Pongratz, Herwig, Ködel, Marlisa, Yang, M., Ashe, Karen H., Walters, Michael A. und Pockes, Steffen (2026) Refinement of Peptidomimetics toward MUR-2425: A Brain-Penetrant and Selective Caspase-2 Inhibitor with Enhanced Pharmacokinetics. Journal of Medicinal Chemistry.

DOI zum Zitieren dieses Dokuments: 10.5283/epub.83190


Zusammenfassung

Caspase-2 (Casp2) has emerged as a promising target for tau-associated neurodegenerative diseases, yet the development of potent, selective, and drug-like inhibitors remains challenging. Here, we report a systematic structure–activity relationship study of 80 novel covalent-reversible peptidomimetic Casp2 inhibitors, revealing key structural features of the Casp2 S2–S3 binding site and ...

Caspase-2 (Casp2) has emerged as a promising target for tau-associated neurodegenerative diseases, yet the development of potent, selective, and drug-like inhibitors remains challenging. Here, we report a systematic structure–activity relationship study of 80 novel covalent-reversible peptidomimetic Casp2 inhibitors, revealing key structural features of the Casp2 S2–S3 binding site and discovering (S)-2-methylindoline-2-carboxylic acid (2-Me-Idc) and quinaldic acid (Quin) as versatile and stable P5 scaffolds. One-step conversion of the aldehyde warhead into a nitrile remarkably enhanced selectivity while maintaning potency. The results culminate in MUR-2425 (87, (2-Me-Idc)(hE)VP*D-CN), a nanomolar Casp2 inhibitor (pKi (cpCasp2) = 7.75) with ≥525-fold selectivity over Casp1/3/4/5/6/7/9/10 and 24-fold over Casp8. MUR-2425 prevents the formation of neurotoxic Δtau314 in vitro, exhibits stable ADMET properties across human, rat, and mouse species and proves brain penetrance after subcutaneous injection in CD-1 mice. MUR-2425 is confirmed to engage Casp2 covalently by cocrystallization, supporting its further development for Alzheimer’s disease and related dementias.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftJournal of Medicinal Chemistry
VerlagACS
Open Access ArtACS Hybrid
Datum5 November 2026
Veröffentlichungsdatum17 Nov 2026 09:21
InstitutionenChemie und Pharmazie > Institut für Pharmazie
Chemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmazeutische / Medizinische Chemie I (Prof. Elz)
Projekte
Gefördert von: Deutsche Forschungsgemeinschaft (DFG) (527849699)
Identifikationsnummer
WertTyp
10.1021/acs.jmedchem.6c01371DOI
Stichwörter / KeywordsInhibitors; Peptides and proteins; Aldehydes; Rodent models; Central nervous system
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenJa
URN der UB Regensburgurn:nbn:de:bvb:355-epub-831900
Dokumenten-ID83190

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben